Download FRUSCIO Robert

CURRICULUM VITAE
Informazioni personali
Nome e Cognome
Data di nascita
Qualifica
Amministrazione
Incarico attuale
Numero telefonico
ufficio
Indirizzo e-mail
istituzionale
Robert Fruscio
16/12/1976
Dirigente Medico
Ospedale San Gerardo
Ginecologia Chirurgica/Ginecologia Oncologica
0392339434
[email protected]
Titoli di studio e professionali ed esperienze lavorative
Titolo di studio 1995: Diploma di Scuola Superiore (Liceo Classico)
2001: Laurea in Medicina e Chirurgia presso l’Universita’ degli
Studi di Milano-Bicocca con il punteggio di 110/110 e lode
Specializzazione 2006: Diploma di Specializzazione in Ostetricia e Ginecologia
2010: Dottore di ricerca in Ginecologia Oncologica
Esperienze Giu ’99 - Lug ‘01: Tesista, Laboratorio di Farmacologia
professionali Antitumorale, Dipartimento di Oncologia, Istituto di Ricerche
Farmacologiche “Mario Negri”, Milano, Italia
(incarichi
ricoperti) Lug ’01 - oggi: Research fellow, Laboratorio di Farmacologia
Antitumorale, Dipartimento di Oncologia, Istituto di Ricerche
Farmacologiche “Mario Negri”, Milano, Italia
Oct ‘01 – Oct ‘06: Iscritto alla Scuola di Specializzazione in
Ostetricia e Ginecologia, l’Universita’ degli Studi di MilanoBicocca, Ospedale San Gerardo, Monza
Mar ’04 – Mar ’05: Research fellow, Laboratorio di Farmacologia
Antitumorale,
Departimento di Medicina, Massachusetts
General Hospital, Harvard University (Boston, MA, USA)
Nov ’06 – Feb ‘10: Iscritto al Dottorato di Ricerca in Ginecologia
Oncologica presso l’Università degli Studi di Milano-Bicocca
da Gen ’07 - oggi: Assunto in qualita’ di dirigente medico presso
la Clinica Ostetrica e Ginecologica, Ospedale San Gerardo,
Monza
da Ott '10 - oggi: Professore a contratto della Scuola di
Specialità in Ginecologia e Ostetricia dell'Università degli Studi
di Milano-Bicocca
da Ott ‘11 - oggi: Professore a contratto del Corso di Laurea di
Ostetricia dell'Università degli Studi di Milano-Bicocca
Capacità
linguistiche
Capacità nell’uso
delle tecnologie
Italiano parlato e scritto (madrelingua)
Inglese parlato e scritto: livello ottimo
Ottime capacità nell'uso di tecnologie per la diagnostica
ultrasonografica in ambito ginecologico
Buone capacità della tecnologia informatica
Altro (partecipazione a
convegni e seminari,
pubblicazioni,
collaborazioni a riviste,
ecc., ed ogni altra
informazione che il
dirigente ritiene di dover
pubblicare)
ALTRI INCARICHI
Da luglio 2002 a luglio 2006 direttore esecutivo del Journal of
Medicine and the Person
Membro dell’ advisory board della rivista internazionale, peer
reviewed “Advances in Therapy”
Membro dell’ advisory board della rivista internazionale, peer
reviewed “Journal of Chinese Clinical Medicine”
Da gennaio 2010 Editore Associato della rivista internazionale,
peer reviewed “BioMed Central Cancer”
Peer-reviewer for diverse riviste internazionali, tra le quali:
Advances in Therapy
Archives of Gynecology and Obstetrics
British Journal of Cancer
Cancer Investigation
Cancer Chemotherapy and Pharmacology
Cancer Epidemiology, Biomarkers and Prevention
Cancer Genetics and Cytogenetics
Cancer Therapy
European Journal of Cancer
European Journal of Obstetrics & Gynecology
Reproductive Biology
Gynecologic Oncology
Gynecological Surgery
International Journal of Gynecology and Obstetrics
Journal of Ecology and the Natural Environment
Oncology
Pediatric Drugs
Surgical Endoscopy
and
Co-investigatore
nello
studio
clinico
multicentrico
randomizzato a doppio cieco di fase 2 con AVE0005 in
pazienti affette da tumore ovarico (ARD6122, sponsorizzato
da Sanofi-Aventis).
Co-investigatore nello studio multicentrico randomizzato di
fase 3 con Pazopanib in pazienti con tumore ovarico dopo
prima linea chemioterapica (AGO/OVAR16, VEG110655
sponsorizzato da GlaxoSmithKline)
Co-investigatore
nello
studio
clinico
multicentrico
randomizzato a doppio cieco di fase 3 con BIBF 1120 in
combinazione con carboplatino e paclitaxel in pazienti con
carcinoma ovarico avanzato (AGO/OVAR12, BI 1199.15,
sponsorizzato da Boehringer Ingelheim)
Co-investigatore nello studio clinico multicentrico di fase 3 con
Bevacizumab in pazienti con carcinoma ovarico (ROSiA study,
MO22923 sponsorizzato da F. Hoffmann-La Roche Ltd.).
Principal Investigator negli studi clinico multicentrici IOTA2,
IOTA3, IOTA5, IETA.
Membro della Società Europea di Ginecologia Oncologica
(ESGO)
Membro della taskforce dell'ESGO sui tumori in gravidanza
(http://www.cancerinpregnancy.org/node/29)
Pubblicazioni scientifiche
1. Sottani C, Colombo T, Zucchetti M, Fruscio R, D'Incalci M,
Minoia C. High-performance liquid chromatography/
tandem mass spectrometry for the quantitative analysis
of a novel taxane derivative (BAY59-8862) in biological
samples and characterization of its metabolic profile in
rat bile samples Rapid Commun Mass Spectrom 2001; 15:
1807-1816
2. D’Incalci M, Erba E, Damia G, Galliera E, Carcassa L,
Marchini S, Tognon G, Fruscio R, Jimeno J Faircloth GT
Unique features of the mode of action of ET-743
Oncologist. 2002;7(3):210-6
3. M. Zaffaroni, R. Frapolli, T. Colombo, R. Fruscio, E.
Bombardelli, P. Morazzoni, A. Riva, M. D’Incalci and M.
Zucchetti High-performance liquid chromatographic assay
for the determination of the novel C-Seco-taxane
derivative (IDN 5390) in mouse plasma Journal of
Chromatography B, 780 (2002) 93-98
4. Lissoni AA, Fei F, Rossi R, Fruscio R, Villa A, Zani G
Ifosfamide in the treatment of malignant epithelial
ovarian tumors Oncology. 2003;65 Suppl 2:59-62
5. Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha
S, Bardelli A, Broggini M PRL-3 phosphatase is implicated
in ovarian cancer growth Clin Cancer Res. 2005 Oct
1;11(19 Pt 1):6835-9
6. Fruscio R, Lissoni AA, Frapolli R, Corso S, Mangioni C,
D'Incalci
M,
Zucchetti
M
Clindamycin-paclitaxel
pharmacokinetic interaction in ovarian cancer patients
Cancer Chemother Pharmacol. 2006 Sep;58(3):319-25
7. Assi F, Fruscio R, Bonardi C, Ghidini A, Allavena P,
Mantovani A, Locatelli A Pentraxin 3 in plasma and vaginal
fluid in women with preterm delivery BJOG, 2007
Feb;114(2):143-7
8. Vecchione F, Fruscio R, Dell’Anna T, Garbi A, Garcia Parra
R, Corso S, Lissoni A A Phase II clinical trial of Topotecan
and Carboplatin in patients with newly diagnosed
advanced epithelial ovarian cancer International Journal
of Gynecological Cancer, 2007 Mar-Apr;17(2):367-72
9. Marchini S, Marabese M, Marrazzo E, Mariani P, Cattaneo D,
Fossati R, Compagnoni A, Fruscio R, Lissoni AA, Broggini M
∆Np63 expression is associated with poor survival in
ovarian cancer Ann Oncol. 2008 Mar;19(3):501-7
10. Fruscio R, Colombo N, Lissoni AA, Garbi A, Fossati R, Ieda'
N, Torri V, Mangioni C A phase II randomised clinical trial
comparing cisplatin, paclitaxel and ifosfamide with
cisplatin, paclitaxel and epirubicin in newly diagnosed
advanced epithelial ovarian cancer: long-term survival
analysis Br J Cancer. 2008 Feb 26;98(4):720-7
11. Signorelli M, Fruscio R, Lissoni AA, Pirovano C, Perego P,
Mangioni C Synchronous early-stage endometrial and
ovarian cancer Int J Gynaecol Obstet. 2008 Jul;102(1):34-8
12. Pellegrino A, Fruscio R, Maneo A, Corso S, Battistello M,
Chiappa V, Stomati M. Harmonic scalpel versus
conventional electrosurgery in the treatment of vulvar
cancer Int J Gynaecol Obstet. 2008 Nov;103(2):185-8
13. Fruscio R, Padula F, Mancini E, Pellegrino A, De Nictolis M.
Malignant transformation of vaginal endometriosis
treated with neoadjuvant chemotherapy and surgery J
Obstet Gynaecol Res. 2008 Aug;34(4 Pt 2):706-8
14. Pellegrino A, Villa A, Fruscio R, Signorelli M, Meroni MG,
Iedà N, Vitobello D.
Total laparoscopic radical
hysterectomy and pelvic lymphadenectomy in early stage
cervical cancer Surg Laparosc Endosc Percutan Tech. 2008
Oct;18(5):474-8
15. Marchini S, Mariani P, Chiorino G, Marrazzo E, Bonomi R,
Fruscio R, Clivio L, Garbi A, Torri V, Cinquini M, Dell'Anna T,
Apolone G, Broggini M, D'Incalci M. Analysis of gene
expression in early-stage ovarian cancer Clin Cancer Res.
2008 Dec 1;14(23):7850-60
16. Pellegrino A, Vizza E, Fruscio R, Villa A, Corrado G, Villa M,
Dell'anna T, Vitobello D. Total laparoscopic radical
hysterectomy and pelvic lymphadenectomy in patients
with Ib1 stage cervical cancer: Analysis of surgical and
oncological outcome Eur J Surg Oncol. 2009 Jan;35(1):98103
17. Pellegrino A, Signorelli M, Fruscio R, Villa A, Buda A,
Beretta P, Garbi A, Vitobello D. Feasibility and morbidity
of total laparoscopic radical hysterectomy with or
without pelvic limphadenectomy in obese women with
stage I endometrial cancer Arch Gynecol Obstet. 2008 Sep
16
18. Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY,
Phillips P, Pollack I, Packer R, Boyett JM, Blaney S,
Banerjee A, Geyer R, Friedman H, Goldman S, Kun LE,
Macdonald T; on behalf of the Pediatric Brain Tumor
Consortium. Phase I study of SU5416, a small molecule
inhibitor of the vascular endothelial growth factor
receptor (VEGFR) in refractory pediatric central nervous
system tumors Pediatr Blood Cancer. 2009 Feb;52(2):169176
19. Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P,
Katsaros D, Chiari S, Buda A, Landoni F, Peiretti M,
Dell'anna T, Fruscio R, Signorelli M, Grassi R, Floriani I,
Fossati R, Torri V, Rulli E. A phase II, randomized trial of
neo-adjuvant chemotherapy comparing a three-drug
combination of paclitaxel, ifosfamide, and cisplatin (TIP)
versus paclitaxel and cisplatin (TP) followed by radical
surgery in patients with locally advanced squamous cell
cervical carcinoma: the Snap-02 Italian Collaborative
Study Ann Oncol. 2009 Apr;20(4):660-5
20. Signorelli M, Chiappa V, Minig L, Fruscio R, Perego P,
Caspani G, Battistello M, Colombo N. Platinum,
anthracycline, and alkylating agent-based chemotherapy
for ovarian carcinosarcoma. Int J Gynecol Cancer. 2009
Aug;19(6):1142-6
21. Trio C, Recalcati D, Sina F, Fruscio R. Intrauterine fallopian
tube incarceration after vacuum aspiration for pregnancy
termination Int J Gynaecol Obstet. 2010 Feb;108(2):157-8
22. Timmerman D, Van Calster B, Testa AC, Guerriero S,
Fischerova D, Lissoni AA, Van Holsbeke C, Fruscio R,
Czekierdowski A, Jurkovic D, Savelli L, Vergote I, Bourne T,
Van Huffel S, Valentin L. Ovarian cancer prediction in
adnexal masses using ultrasound-based logistic regression
models: a temporal and external validation study by the
IOTA group Ultrasound Obstet Gynecol. 2010 Aug;36(2):22634
23. Daemen A, Valentin L, Fruscio R, Van Holsbeke C, Melis GB,
Guerriero S, Czekierdowski A, Jurkovic D, Ombelet W, Rossi
A, Vergote I, Bourne T, De Moor B, Timmerman D.
Improving the preoperative classification of adnexal
masses as benign or malignant by second stage tests
Ultrasound Obstet Gynecol. 2011 Jan;37(1):100-6
24. Daemen A, Jurkovic D, Van Holsbeke C, Guerriero S, Testa
AC, Czekierdowski A, Fruscio R, Paladini D, Neven P, Rossi
A, Bourne T, De Moor B, Timmerman D. The effect of
cancer prevalence on the use of different cut-off levels
and the performance of mathematical models to
distinguish benign from malignant adnexal masses
Ultrasound Obstet Gynecol. 2011 Feb;37(2):226-31
25. Signorelli M, Fruscio R, Dell'Anna T, Buda A, Giuliani D,
Ceppi L, Milani R. Lymphadenectomy in uterine low-grade
endometrial stromal sarcoma: an analysis of 19 cases and
a literature review Int J Gynecol Cancer. 2010
Nov;20(8):1363-6
26. Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB,
Guerriero S, Van Holsbeke C, Savelli L, Fruscio R, Lissoni
AA, Testa AC, Veldman J, Vergote I, Van Huffel S, Bourne T,
Valentin L. Simple ultrasound rules to distinguish between
benign and malignant adnexal masses before surgery:
prospective validation by IOTA group BMJ. 2010 Dec
14;341
27. Vizza E, Pellegrino A, Milani R, Fruscio R, Baiocco E,
Cognetti F, Savarese A, Tomao F, Chen C, Corrado G. Total
laparoscopic
radical
hysterectomy
and
pelvic
lymphadenectomy in locally advanced stage IB2-IIB
cervical cancer patients after neoadjuvant chemotherapy
Eur J Surg Oncol. 2011 Apr;37(4):364-9
28. Ganzinelli M, Mariani P, Cattaneo D, Fossati R, Fruscio R,
Corso S, Ricci F, Broggini M, Damia G. Expression of DNA
repair genes in ovarian cancer samples: Biological and
clinical considerations Eur J Cancer. 2011 May;47(7):108694
29. Fruscio R, Garbi A, Parma G, Lissoni AA, Garavaglia D,
Bonazzi CM, Dell'anna T, Mangioni C, Milani R, Colombo N.
Randomized phase III clinical trial evaluating weekly
cisplatin for advanced epithelial ovarian cancer J Natl
Cancer Inst. 2011 Feb 16;103(4):347-51
30. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D,
Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame L,
Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G,
Buda A, Romualdi C, D'Incalci M. Association between miR200c and the survival of patients with stage I epithelial
ovarian cancer: a retrospective study of two independent
tumour
tissue
collections
Lancet
Oncol.
2011
Mar;12(3):273-85
31. Valentin L, Ameye L, Savelli L, Fruscio R, Leone F,
Czekierdowski A, Lissoni A, Fischerova D, Guerriero S, Van
Holsbeke C, Van Huffel S, Timmerman D. Adnexal masses
difficult to classify as benign or malignant using
subjective assessment of gray scale and Doppler
ultrasound findings: logistic regression models do not
help Ultrasound Obstet Gynecol. 2011 Oct;38(4):456-65
32. Signorelli M, Guerra L, Montanelli L, Crivellaro C, Buda A,
Dell'anna T, Picchio M, Milani R, Fruscio R, Messa C.
Preoperative staging of cervical cancer: Is 18-FDG-PET/CT
really effective in patients with early stage disease?
Gynecol Oncol. 2011 Nov;123(2):236-40
33. Van Holsbeke CD, Van Calster B, Bourne T, Ajossa S, Testa
AC, Guerriero S, Fruscio R, Lissoni AA, Czekierdowski A,
Savelli L, Van Huffel S, Valentin L, Timmerman D. External
validation of diagnostic models to estimate the risk of
malignancy in adnexal masses Clin Cancer Res. 2012 Feb
1;18(3):815-25. Epub 2011 Nov 23
34. Silini A, Ghilardi C, Figini S, Sangalli F, Fruscio R, Dahse R,
Pedley RB, Giavazzi R, Bani M. Regulator of G-protein
signaling 5 (RGS5) protein: a novel marker of cancer
vasculature elicited and sustained by the tumor's
proangiogenic microenvironment Cell Mol Life Sci. 2012
Apr;69(7):1167-78. Epub 2011 Dec 1.
35. Caiola E, Porcu L, Fruscio R, Giuliani D, Milani R, Torri V,
Broggini M, Marabese M. DNA-damage response gene
polymorphisms and therapeutic outcomes in ovarian
cancer Pharmacogenomics J. 2011 Dec 13.
36. Mosig RA, Lobl M, Senturk E, Shah H, Cohen S, Chudin E,
Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, Dottino
P, Martignetti JA. IGFBP-4 tumor and serum levels are
increased across all stages of epithelial ovarian cancer. J
Ovarian Res. 2012 Jan 20;5(1):3
37. Mosig RA, Lin L, Senturk E, Shah H, Huang F, Schlosshauer
P, Cohen S, Fruscio R, Marchini S, D'Incalci M,
Sachidanandam R, Dottino P, Martignetti JA. Application of
RNA-Seq
transcriptome
analysis:
CD151
is
an
Invasion/Migration target in all stages of epithelial ovarian
cancer. J Ovarian Res. 2012 Jan 24;5:4
38. Buda A, Fruscio R, Pirovano C, Signorelli M, Betti M, Milani
R. The use of TachoSil for the prevention of
postoperative complications after groin dissection in
cases of gynecologic malignancy. Int J Gynaecol Obstet.
2012 Jun;117(3):217-9
39. Buda A, Confalonieri PL, Rovati LC, Fruscio R, Giuliani D,
Signorelli M, Dell'anna T, Pirovano C, Milani R. Better
Anatomical and Cosmetic Results Using Tunneled Lotus
Petal Flap for Plastic Reconstruction After Demolitive
Surgery for Vulvar Malignancy. Int J Gynecol Cancer. 2012
Jun;22(5):860-4
40. Fadini R, Dal Canto M, Mignini Renzini M, Milani R, Fruscio
R, Cantù MG, Brambillasca F, Coticchio G. Embryo transfer
following in vitro maturation and cryopreservation of
oocytes recovered from antral follicles during
conservative surgery for ovarian cancer. J Assist Reprod
Genet. 2012 Aug;29(8):779-81
41. Ricci F, Bernasconi S, Perego P, Ganzinelli M, Russo G, Bono
F, Mangioni C, Fruscio R, Signorelli M, Broggini M, Damia G.
Ovarian carcinoma tumor-initiating cells have a
mesenchymal phenotype. Cell Cycle. 2012 May 15;11(10).
42. Fruscio R, Villa A, Chiari S, Vergani P, Ceppi L, Dell'Orto F,
Dell'Anna T, Chiappa V, Bonazzi CM, Milani R, Mangioni C,
Locatelli
A.
Delivery
delay
with
neoadjuvant
chemotherapy for cervical cancer patients during
pregnancy: a series of nine cases and literature review.
Gynecol Oncol. 2012 Aug;126(2):192-7
43. Caiola E, Rulli E, Fruscio R, Buda A, Broggini M, Marabese M.
KRas-LCS6 polymorphism does not impact on outcomes in
ovarian cancer. Am J Cancer Res. 2012;2(3):298-308
44. Marchini S, Poynor E, Barakat RR, Clivio L, Cinquini M,
Fruscio R, Porcu L, Bussani C, D'Incalci M, Erba E, Romano
M, Cattoretti G, Katsaros D, Koff A, Luzzatto L. The zinc
finger gene ZIC2 has features of an oncogene and its
overexpression correlates strongly with the clinical
course of epithelial ovarian cancer. Clin Cancer Res. 2012
Aug 15;18(16):4313-24
45. Fruscio R, Mangioni C, Milani R. Reply to: Are the
outcomes of neoadjuvant chemotherapy for stage Ib2
cervical cancer similar in pregnant and nonpregnant
patients? Gynecol Oncol. 2012 Oct;127(1):258-9
46. Crivellaro C, Signorelli M, Guerra L, De Ponti E, Buda A,
Dolci C, Pirovano C, Todde S, Fruscio R, Messa C. 18F-FDG
PET/CT can predict nodal metastases but not recurrence
in early stage uterine cervical cancer. Gynecol Oncol.
2012 Oct;127(1):131-5
47. Franchi D, Boveri S, Fruscio R, Fischerova D, Guerriero S,
Moruzzi M, Colombo N, Timmerman D, Valentin L, Testa AC.
Imaging in gynecological disease (8): ultrasound
characteristics of ovarian borderline tumor recurrence.
Ultrasound
Obstet
Gynecol.
2012
Aug
1.
doi:
10.1002/uog.12276. [Epub ahead of print]
48. Dell' Anna T, Signorelli M, Benedetti-Panici P, Maggioni A,
Fossati R, Fruscio R, Milani R, Bocciolone L, Buda A,
Mangioni C, Scambia G, Angioli R, Campagnutta E, Grassi R,
Landoni F. Systematic lymphadenectomy in ovarian
cancer at second-look surgery: a randomised clinical
trial. Br J Cancer. 2012 Aug 21;107(5):785-92
49. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini
IF, Cavalieri D, Chiorino G, Cattoretti G, Mangioni C, Milani
R, Torri V, Romualdi C, Zambelli A, Romano M, Signorelli M,
Giandomenico SD, D'Incalci M. Resistance to platinumbased chemotherapy is associated with epithelial to
mesenchymal transition in epithelial ovarian cancer. Eur
J Cancer. 2012 Aug 13. [Epub ahead of print]
50. Valentin L, Ameye L, Savelli L, Fruscio R, Leone F,
Czekierdowski A, Lissoni A, Fischerova D, Guerriero S, Van
Holsbeke C, Van Huffel S, Timmerman D. Unilocular
adnexal cysts with papillary projections but no other
solid components: is there a diagnostic method that can
reliably classify them as benign or malignant before
surgery? Ultrasound Obstet Gynecol. 2012 Aug 23. doi:
10.1002/uog.12294. [Epub ahead of print]
51. Fruscio R, Corso S, Ceppi L, Garavaglia D, Garbi A, Floriani
I, Franchi D, Cantù MG, Bonazzi CM, Milani R, Mangioni C,
Colombo N. Conservative management of early-stage
epithelial ovarian cancer: results of a large retrospective
series. Ann Oncol. 2012 Sep 3. [Epub ahead of print]
52. Valentin L, Ameye L, Franchi D, Guerriero S, Jurkovic D,
Savelli L, Fischerova D, Lissoni A, Van Holsbeke C, Fruscio
R, Van Huffel S, Testa A, Timmerman D. The risk of
malignancy in unilocular cysts: a study on 1148 adnexal
masses classified as unilocular cysts at transvaginal scan
with review of the literature. Ultrasound Obstet Gynecol.
2012 Sep 24. doi: 10.1002/uog.12308. [Epub ahead of print]
Relazioni a congressi
• Dermoid ovarian cysts: diagnostic value of sonography 13th World Congress on Ultrasound in Obstetrics and
Gynecology, Parigi, Settembre 2003
• Fattibilità
e
laparoscopica
morbosità
dell’istrectomia
radicale
(con
linfoadenctomia
pelvica)
nel
carcinoma dell’endometrio e nel sarcoma dell’utero 82mo Congresso della Societa’ Italiana di Ginecologia ed
Ostetricia (SIGO), Roma, Ottobre 2006
• Total radical laparoscopic hysterectomy and pelvic
lymphadenectomy in early-stage cervical cancer: analysis
of feasibility and oncologic outcome - Advances in
Gynaecological Oncology, 19° Congresso Nazionale SIOG,
Milano, Giugno 2007
• Terapia laparoscopica conservativa nel carcinoma
dell’ovaio - Stato dell’arte dell’endoscopia in oncologia
ginecologica, San Giovanni Rotondo, 27 – 28 Sttembre 2007
• La neoplasia della vulva: protocolli terapeutici chirurgici
e nuove tecniche – IX Congresso Nazionale SIGiTE, Mesagne
(Brindisi), 18 – 21 Giugno 2008
• Bersagli molecolari nella terapia del carcinoma ovarico IX Congresso Nazionale SIGiTE, Mesagne (Brindisi), 18 – 21
Giugno 2008
•
Long-term results from a randomized phase III clinical
trial evaluating weekly cisplatin administration in newly
diagnosed epithelial advanced ovarian cancer – ESGO
Congress, Belgrade (Serbia), October 11 – 14, 2009